ULTRAGENYX PHARMACEUTICAL INC. Exchange Rate Effect on Cash
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Exchange Rate Effect on Cash of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2026-03-31 was -$1.00M, a 200.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2025-03-31 was $1.00M.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2024-03-31 was -$679.00K, a 421.80% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2023-03-31 was $211.00K.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2025 was $4.00M.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2024 was -$2.00M.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2023 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2022 was -$1.07M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 3 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 12 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | -$1.00M 10-Q · filed 2026-05-06 | ||||||
| 2025-12-31 | $4.00M 10-K · filed 2026-02-18 | ||||||
| 2025-09-30 | $4.66M 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | $5.00M 10-Q · filed 2026-08-05 | $4.36M 10-Q · filed 2025-08-06 | |||||
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-06 | $1.45M 10-Q · filed 2025-05-07 | |||||
| 2024-12-31 | -$2.00M 10-K · filed 2026-02-18 | -$2.52M 10-K · filed 2025-02-19 | |||||
| 2024-09-30 | -$52.00K 10-Q · filed 2025-11-05 | ||||||
| 2024-06-30 | -$1.33M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | -$679.00K 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-18 | $462.00K 10-K · filed 2024-02-21 | |||||
| 2023-09-30 | -$641.00K 10-Q · filed 2024-11-06 | ||||||
| 2023-06-30 | $75.00K 10-Q · filed 2024-08-02 | ||||||
| 2023-03-31 | $211.00K 10-Q · filed 2024-05-03 | ||||||
| 2022-12-31 | -$1.07M 10-K · filed 2025-02-19 | ||||||
| 2022-09-30 | -$2.43M 10-Q · filed 2023-11-03 | ||||||
| 2022-06-30 | -$1.35M 10-Q · filed 2023-08-04 | ||||||
| 2022-03-31 | -$108.00K 10-Q · filed 2023-05-05 | ||||||
| 2021-12-31 | -$1.19M 10-K · filed 2024-02-21 | ||||||
| 2021-09-30 | -$802.00K 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | -$323.00K 10-Q · filed 2022-07-29 | ||||||
| 2021-03-31 | -$771.00K 10-Q · filed 2022-05-06 | ||||||
| 2020-12-31 | $1.12M 10-K · filed 2023-02-17 | ||||||
| 2020-09-30 | $239.00K 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | -$198.00K 10-Q · filed 2021-08-03 | ||||||
| 2020-03-31 | -$623.00K 10-Q · filed 2021-05-05 | ||||||
| 2019-12-31 | -$165.00K 10-K · filed 2022-02-15 | ||||||
| 2019-09-30 | -$502.00K 10-Q · filed 2020-10-27 | ||||||
| 2019-06-30 | -$30.00K 10-Q · filed 2020-07-30 | ||||||
| 2019-03-31 | -$198.00K 10-Q · filed 2020-05-07 | ||||||
| 2018-12-31 | -$472.00K 10-K · filed 2021-02-12 | ||||||
| 2018-09-30 | -$617.00K 10-Q · filed 2019-11-06 | ||||||
| 2018-06-30 | -$647.00K 10-Q · filed 2019-08-02 | ||||||
| 2018-03-31 | $249.00K 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | $528.00K 10-K · filed 2020-02-14 | ||||||
| 2017-09-30 | $167.00K 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | -$361.00K 10-Q · filed 2018-08-03 | ||||||
| 2016-12-31 | -$65.00K 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |